Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2007

View Archived Issues

Parathyroid hormone (1-84) reduces vertebral fracture risk in postmenopausal women

Novel treatment options for urological disorders claimed in recent patents

Recent patents disclose new therapeutic agents for depression and psychosis

Novel therapeutic options for inflammatory disorders disclosed in recent patents

New treatment strategy for HIV infection disclosed in recent GSK patent

Genentech extends research collaboration with Seattle Genetics

BioCryst updates Fodosine development program

ADH-1 plus melphalan studied for treatment of melanoma

StormBio and Imperial Innovations sign agreement for pandemic flu treatment

Yale scientist receives funding to study nanoparticle therapy for prostate cancer

PF-03187207 begins clinical testing for glaucoma

Oxford BioMedica and sanofi-aventis enter agreement for TroVax

Acuity, Froptix and eXegenics to merge to form Opko

SRI and Blanca to jointly develop Blanca's carbacephem antibiotic drug candidates

MorphoSys and Astellas enter antibody partnership

Positive findings for MN-166 in relapsing MS

AS-1552133 shows improved preclinical cholesterol- and triglyceride-lowering activity

The HER/VEGFR2 inhibitor BMS-690514, a clinical candidate for the treatment of solid tumors

Kyorin's PAA-3352 shows antidiabetic activity in vivo

New experimental approaches in glaucoma therapy

CeNeS files first IND for M6G

Carrington and IVI collaborate on sublingual vaccine development

PRX-302 begins phase I study for BPH

Pieris antitumor activity of VEGF-specific Anticalin in preclinical studies

High concentrations of AR-709 reached in key lung compartments

ACE-393 completes phase I trials for travelers' diarrhea

NDA filing for methylnaltrexone for treatment of opioid-induced constipation

Orencia recommended for approval in E.U. for rheumatoid arthritis

Approvable letter for Nuvigil

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...